Nasdaq · Healthcare
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
As-reported financials and recent SEC filings for SUPERNUS PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$719.0M
Net income
$-38.5M
Net margin
-5.4%
Diluted EPS
$-0.68
ROE
-3.6%
P/E (TTM)
—
Market cap
$2.72B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M |
| Gross profit | $644.4M | $583.9M | $523.7M | $580.0M | — |
| Operating income | $-62.3M | $81.7M | $-5.3M | $46.1M | $86.0M |
| Net income | $-38.5M | $73.9M | $1.3M | $60.7M | $53.4M |
| Diluted EPS | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-06-22
View on EDGAR →8-K2026-06-18
View on EDGAR →8-K2026-05-20
View on EDGAR →10-Q2026-05-05
View on EDGAR →8-K2026-05-05
View on EDGAR →SCHEDULE 13G2026-04-30
View on EDGAR →ARS2026-04-30
View on EDGAR →DEFA14A2026-04-30
View on EDGAR →Go deeper on SUPN
Search SUPERNUS PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.